Abstract
Gastric cancer shows a strong male predominance, and sex steroid hormones have been hypothesized to explain this sex disparity. Previous studies examining the associations between sex hormones and sex hormone binding globulin (SHBG) and risk of gastric cancer come primarily from western populations and additional studies in diverse populations will help us better understand the association. We performed a nested case-control study in Linxian Nutrition Intervention Trials cohorts to evaluate the associations among Chinese men, where we had sufficient cases to perform a well-powered study. Using radioimmunoassays and immunoassays, we quantitated androgens, estrogens, and SHBG in baseline serum from 328 men that developed non-cardia gastric cancer and matched controls. We used multivariable unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) and explored interactions with body mass index (BMI), age, alcohol drinking, smoking, and follow-up time. Subjects with SHBG in the highest quartile, as compared to those in the lowest quartile, had a significantly increased risk of gastric cancer (OR=1.87, 95% CI=1.01, 3.44). We found some evidence for associations of sex steroid hormones in men with lower BMI. Our study found a novel association suggesting that higher serum concentrations of SHBG may be associated with risk of gastric cancer in men. We found no overall associations with sex hormones themselves, but future studies should expand the scope of these studies to include women and further explore whether BMI modifies a potential association.
Keywords: sex steroid hormones, SHBG, gastric cancer, Chinese men
Introduction
Gastric cancer is the fifth most common cancer and ranks the third in mortality worldwide (1). In 2018, an estimated 1,033,701 individuals were diagnosed of gastric cancer and 782,685 patients died of this disease (1), which impose a severe health burden especially in developing countries. In China alone, approximately 390,000 people died from gastric cancer every year, which accounts for 50% of global death cases (1–3). Anatomically, gastric cancer can be classified into cardia and non-cardia gastric cancer which are characterized by distinct risk factors and clinical feature and both of them have a high incidence in Linxian, China (4).
Age-standardized incidence rates of gastric cancer show a male predominance with a male-to-female rate of more than 2:1 in most populations (1,5). This difference, however, cannot be entirely attributed to the different prevalence of established risk factors, such as smoking (6) and Helicobacter pylori infection (7) between two sexes. Limited studies suggest endogenous sex steroid hormones and sex hormone binding globulin (SHBG, a modulator of hormones bioavailability) may be associated with gastric cancer (8,9). Independently, epidemiological studies show that men receiving anti-androgen therapies for prostate cancer may have a lower risk of gastric cancer (10), whereas antiestrogen drugs, e.g., tamoxifen in women may increase the risk (9). It is biologically plausible that sex steroid hormones involve in the pro-inflammatory state (11,12). A decrease testosterone levels has been associated with increasing levels of inflammatory cytokines in aging men (13) and estrogen-related receptors function has been reported as a potential tumor suppressor in gastric cancer (14–16).
However, whether serum sex steroid hormone and SHBG are associated with incident gastric cancer remains unclear. For example, an epidemiologic study reported no association between hormone replacement therapy and gastric cancer in a large prospective study of women (17). Additionally, most current evidence comes from Western studies of mostly white subjects and there is no data from Chinese subjects. Cancer rates are strongly population dependent as does sex hormone status which may lead to different association in different population (18). Therefore, we investigated whether serum levels of androgens (androstendione and testosterone), estrogens (estradiol and estrone), and SHBG were associated with primary non-cardia gastric risk in Chinese males.
Materials and Methods
Study population and blood sample collection
We designed a nested case-control study within the Linxian Nutrition Intervention Trial (NIT), including the Dysplasia Trial (19) and the General Population Trial (20) (Supplementary Table 1). The Dysplasia Trial enrolled 3,318 individuals aged 40 to 69 years with esophageal dysplasia in three communes of northern Linxian, China. Subjects were randomized and received either multiple vitamin/mineral supplements (14 vitamins and 12 minerals) or placebos for 6 years, beginning in May 1985 (19). The General Population Trial recruitment commenced in March 1986 and a total of 29,584 healthy villagers of the same age group were randomly assigned to receive four daily vitamin/mineral supplement combinations for 5.25 years from March 1986 to May 1991 in a one-half replicate of a 24 fractional factorial experimental design (20). Each subject was interviewed, given a brief physical examination, and had 10 ml of blood drawn. After collection, serum specimens were separated, aliquoted, and stored frozen at −70°C for future analyses. The study was performed according to the guidelines of the Helsinki declaration. Ethical approval was obtained through the Institutional Review Boards of the U.S. National Institutes of Health and the Chinese Academy of Medical Science (Beijing, China), and all subjects gave written informed consent.
Cases of incident primary gastric cancer was defined using the International Classification of Diseases, 10th edition code for non-cardia gastric cancer (i.e., C16.1–C16.8) and were ascertained by the Linxian Cancer and Death Registries Data. Diagnostic materials (case records, endoscopy and pathology slides) for cases were reviewed and confirmed by a panel of American and Chinese experts (1985–1996) or senior Chinese diagnosticians from Beijing (after 1996) and nearly all cases were confirmed as adenocarcinomas. Loss to follow-up was minimal by 2016 (n=381, or 1.3%) (21).
Through the 15 years of observation between baseline blood draw and cancer diagnosis (from May 1991 to May 2006; median follow-up time, 12.25 years), 560 (213 female and 347 male) cases of incident primary non-cardia gastric cancer were diagnosed in the NIT cohort. For the current study, we selected the 328 male cases with sufficient available serum for analysis, including 31 cases from the Dysplasia Trial and 297 cases from the General Population Trial. There were no significant differences on characteristics between the included cases and overall cases. The 1:1 matched controls were male cancer-free subjects sampled from the same trial subjects with a blood sample, matched by age at start of pills (±3 years), date of blood collection (±31 days) and trials.
Laboratory Assays and Measurements
Estrone, total estradiol, and testosterone were measured by validated radioimmunoassays after organic solvent extraction and Celite column partition chromatography (22,23). SHBG was measured by direct immunoassays using the Immulite analyzer (Diagnostic Products Corporation, Inglewood, CA, USA). Free estradiol and free testosterone concentrations were calculated from measured estradiol, total testosterone, and SHBG with albumin assumed to be a constant (40 g/l) using the method by Sodergard and colleagues according to the law of mass action (24). Figure 1 depicts metabolism and existence forms of sex steroid hormones examined in the current study.
Figure 1. Schematic of sex steroid hormones metabolism and existence forms.
Sex hormone binding globulin (SHBG) is a glycoprotein mainly produced by the liver and secreted into the circulation, which is not part of the sex metabolism pathway. The main function of SHBG is as a carrier protein of sex steroid hormones. Testosterone and estrogen compete with the same binding site, while testosterone has higher binding affinity than estradiol and estrone. When testosterone and estradiol are not bound to SHBG, they are referred to as “free”, or “bioavailable”, and can freely exert their effects upon your body.
Sex steroid hormones and SHBG measurements were conducted in 18 batches and each batch except for the last one included 41 samples (every 38 samples including 19 cases and 19 controls were accompanied by three pooled serum samples as internal controls). The three blinded quality control samples collected from the same subject were analyzed consecutively as triplets within each batch to minimize the laboratory variation between samples from the same subject. Using a nested components of variance analysis, with logarithmically transformed quality control measurements across all batches (25), the estimated overall (intrabatch and interbatch) coefficients of variation for estrone, estradiol, testosterone, and SHBG were 4.3–20.0%. Laboratory personnel were blinded as to the identity of cases, controls, and quality control samples.
Covariates measurements
Demographic characteristics included age and body mass index (BMI). We categorized age as ≤56 and >56 years by median to ensure each level had sufficient and similar number of observations when looking at interactions but we used age as a continuous variable when adjusting for confounding. We first defined BMI according to the standard cutoff points by the Work Group on Obesity in China (WGOC) in categories of underweight: ≤18.5 kg/m2, normal: >18.5–≤24 kg/m2, overweight: >24.0–≤28.0 kg/m2, and obese: >28.0 kg/m2 (26), and then we reclassified BMI as dichotomous variable by median (≤21.2 kg/m2 and >21.2 kg/m2) because almost all (89.63%) subjects had underweight and normal weight. Health-related lifestyle indicators, including alcohol drinking (yes: any alcoholic beverage consumption in the last 12 months, or no: no alcohol consumption in the last 12 months) and smoking status (yes: any regular tobacco consumption including cigarettes or pipes, or no: never smoked), were included for analysis. Helicobacter pylori seropositivity and pepsinogen I/pepsinogen II ratio were measured in some subjects in previous studies (27), but were not considered further due to their incomplete coverage of this subset of the current cohort. Associations between Helicobacter pylori and gastric cancer show modest effect sizes in previous study due to the overall high infection rate. Trials included the Dysplasia Trial and the General Population Trial.
Statistical analysis
Baseline demographic characteristics were summarized by case and control groups. Continuous variables were reported as medians and interquartile ranges (IQR). Categorical variables were described as number of observations and percentages (%). Differences in potential covariates between cases and controls were assessed by Wilcoxon-Mann-Whitney test for continuous variables and the chi-square test for categorical variables. The correlation between exposures were evaluated using Pearson’s correlation coefficients among log10-transformed values of exposures in the controls. Pearson correlation coefficients were used to examine the magnitude of the correlation, as well as the direction of the relationship between sex steroid hormones and SHBG.
We used unconditional logistic regression to analyze the matched data with no loss of validity and a possible increase in precision, and estimate odds ratios (OR) and 95% CIs for the association of incident gastric cancer with sex steroid hormones and SHBG. We firstly conducted crude logistic regression for each hormone and SHBG, respectively. We then conducted multivariable logistic regression for each sex steroid hormone and adjusted for age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, and other related sex steroid hormones or SHBG. We treated the sex hormone levels as continuous variables, scaled to logarithm base 10 of hormone levels in the model. We also used quartiles metric of sex steroid hormones to assess the association. A very small fraction (approximately 1%) of subjects had extremely high or low values of sex steroid hormones, which were unreliable based on a priori knowledge; thus, the outliers above the logarithm base 10 of sex hormone levels±4SD were excluded from analysis.
Age and BMI have been reportedly influencing the levels of sex steroid hormones and involved in gastric carcinogenesis (28–30). Therefore, we conducted subgroup analysis stratified by these two dichotomous variables to explore if there were interactions between sex steroid hormones and these factors. In addition, we estimated OR for alcohol drinking, smoking, and tertiles of follow-up (≤5 years, >5 to ≤10 years or >10 years). One set of sensitivity analysis restricted to the General Population Trial population was conducted in addition to the primary logistic regression models. For current analysis, two-sided p-values <0.05 were considered to be statistically significant. All statistical analyses were conducted in February 2020 using Stata, version 15.0 (College Station, TX: StataCorp, LLP).
Results
Table 1 shows the distributions of demographic and potential risk factors by case and control groups of men in this subset of the NIT cohorts. There were no significant differences between the case and control groups for age at baseline, alcohol drinking, smoking status, androstenedione, testosterone, free testosterone, FT_AT, estradiol, estrone, free estradiol, FE2_AE2, or SHBG (ps>0.05). Compared to controls, subjects who developed gastric cancer were more likely to have a lower BMI (continuous variable, p<0.01) or BMI≤21.2 kg/m2 (dichotomous variable, p=0.04). Supplementary Table 2 shows the correlations between sex steroid hormones and SHBG. We found that free testosterone was highly correlated with free and bioavailable testosterone (FT_AT) (Pearson’s R=0.97), and as well as free estradiol and free and bioavailable estradiol (FE2_AE2) (Pearson’s R=1.00).
Table 1.
Selected characteristic of the cases and controls
| Variable | Overall (n=656) | Controls (n=328) | Cases (n=328) | p-valuea |
|---|---|---|---|---|
| Age at baseline, median (IQR) | 56.00 (49.00, 62.00) | 56.00 (49.00–61.50) | 56.00 (49.00, 62.00) | 0.57 |
| BMI (kg/m2), median (IQR) | 21.2 (20.08, 22.50) | 21.45 (20.28, 22.68) | 21.00 (19.84, 22.12) | <0.01 |
| ≤21.2, N (%)b | 326 (49.70) | 150 (45.73) | 176 (53.66) | 0.04 |
| >21.2 | 330 (50.30) | 178 (54.27) | 152 (46.34) | |
| Alcohol Drinking, N (%)b | 0.57 | |||
| No | 423 (64.48) | 208 (63.41) | 215 (65.55) | |
| Yes | 233 (35.52) | 120 (36.59) | 113 (34.45) | |
| Smoking, N (%)b | 0.55 | |||
| No | 203 (30.95) | 98 (29.88) | 105 (32.01) | |
| Yes | 453 (69.05) | 230 (70.12) | 223 (67.99) | |
| Sex hormones, median (IQR) | ||||
| Androstenedione (ng/ml) | 1.07 (0.88, 1.29) | 1.07 (0.88–1.29) | 1.08 (0.88–1.29) | 0.86 |
| Testosterone (ng/ml) | 8.05 (6.66, 9.56) | 8.13 (6.58–9.78) | 7.95 (6.69–9.36) | 0.41 |
| Free testosterone (pg/ml) | 150.19 (128.93, 178.49) | 153.82 (130.46–180.66) | 148.27 (126.32–174.25) | 0.10 |
| FT_AT (pg/ml) | 3.71 (3.20, 4.39) | 3.78 (3.23–4.45) | 3.67 (3.14–4.29) | 0.10 |
| Estradiol (pg/ml) | 41.63 (33.14, 50.91) | 41.48 (32.35–51.01) | 42.09 (33.76–50.65) | 0.97 |
| Estrone (pg/ml) | 63.17 (51.90, 75.07) | 63.65 (52.92–76.21) | 62.44 (50.65–73.73) | 0.20 |
| Free estradiol (pg/ml) | 1.01 (0.80, 1.26) | 1.00 (0.80–1.27) | 1.01 (0.81–1.25) | 0.72 |
| FE2_AE2 (pg/ml) | 25.60 (20.44, 32.10) | 25.52 (20.29–32.36) | 25.61 (20.56–31.63) | 0.72 |
| SHBG (nmol/L) | 46.80 (38.00, 59.20) | 46.35 (36.75–58.20) | 47.60 (39.15–60.15) | 0.12 |
The p-values for alcohol drinking and smoking were calculated from χ2 test; The p-values for age at baseline, BMI, sex steroid hormones, and SHBG were calculated from Wilcoxon-Mann-Whitney test.
Column percentage was reported for the overall sample.
Abbreviation: BMI, body mass index; FE2_AE2, free and bioavailable estradiol; FT_AT, free and bioavailable testosterone; IQR, interquartile range; OR, odds ratio; SD, standard deviation; SHBG, sex hormone binding globulin.
Table 2 presents associations between the six sex steroid hormones, SHBG, and the risk of gastric cancer. There were no overall associations between sex steroid hormone concentrations (androstenedione, testosterone, FT_AT, estradiol, estrone, and FE2_AE2) and risk of gastric cancer in men. None of the risk estimates or the p-trend was statistically significant for these sex steroid hormones. Subjects with serum SHBG in highest quartile, as compared to those in lowest quartile, had an increased risk of gastric cancer in a crude model (OR=1.71, 95% CI=1.08, 2.71, p-trend=0.09). Results for quartiles of SHBG remained unchanged after adjustment for multiple covariates (OR quartile 4 vs.1=1.87, 95% CI=1.01, 3.44), although no monotonic trends were observed (p-trend=0.12); effect measure was non-significant in linear regression (OR=1.71, 95%CI=0.85, 3.44).
Table 2.
ORs (95%CIs) for gastric cancer in men associated with quartiles of serum concentrations of androgens, estrogens, and SHBG
| Sex hormones | Case/ controls | Continuous (log10) | Quartile | ||||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | p-trenda | |||
| OR (95%CI) | REF | OR (95%CI) | OR (95%CI) | OR (95%CI) | |||
| Androstenedione | ≤0.88 | >0.88–≤1.07 | >1.07–≤1.29 | >1.29 | |||
| Crude | 328/327 | 0.90 (0.53, 1.52) | 1.00 | 1.00 (0.65, 1.54) | 1.04 (0.67, 1.60) | 1.08 (0.69, 1.67) | 0.71 |
| Adjustedb | 325/327 | 0.89 (0.51, 1.55) | 1.00 | 1.06 (0.68, 1.66) | 1.07 (0.68, 1.67) | 1.11 (0.70, 1.77) | 0.66 |
| Testosterone | ≤6.58 | >6.58–≤8.13 | >8.13–≤9.78 | >9.78 | |||
| Crude | 323/328 | 1.02 (0.60, 1.75) | 1.00 | 1.39 (0.90, 2.14) | 1.15 (0.74, 1.79) | 0.94 (0.60, 1.48) | 0.60 |
| Adjustedb | 323/328 | 0.63 (0.30, 1.31) | 1.00 | 1.10 (0.69, 1.74) | 0.84 (0.51, 1.38) | 0.63 (0.36, 1.11) | 0.07 |
| FT_AT | ≤3.25 | >3.25–≤3.79 | >3.79–≤4.45 | >4.45 | |||
| Crude | 323/327 | 0.76 (0.43, 1.36) | 1.00 | 0.86 (0.56, 1.32) | 0.89 (0.58, 1.37) | 0.73 (0.47, 1.13) | 0.20 |
| Adjustedd | 323/327 | 0.70 (0.38, 1.30) | 1.00 | 0.81 (0.52, 1.26) | 0.87 (0.56, 1.35) | 0.68 (0.43, 1.08) | 0.16 |
| Estradiol | ≤32.35 | >32.35–≤41.48 | >41.48–≤51.01 | >51.01 | |||
| Crude | 325/328 | 1.10 (0.69,1.74) | 1.00 | 1.47 (0.94, 2.28) | 1.38 (0.88, 2.14) | 1.23 (0.79, 1.94) | 0.48 |
| Adjustedc | 323/328 | 1.22 (0.73, 2.04) | 1.00 | 1.46 (0.93, 2.31) | 1.45 (0.91, 2.31) | 1.34 (0.83, 2.17) | 0.30 |
| Estrone | ≤53.14 | >53.14–≤63.86 | >63.86–≤76.23 | >76.23 | |||
| Crude | 327/326 | 0.59 (0.35, 0.99) | 1.00 | 0.67 (0.44, 1.04) | 0.84 (0.55, 1.28) | 0.70 (0.46, 1.08) | 0.21 |
| Adjustedc | 322/326 | 0.67 (0.38, 1.18) | 1.00 | 0.68 (0.43, 1.06) | 0.84 (0.54, 1.30) | 0.77 (0.49, 1.22) | 0.41 |
| FE2_AE2 | ≤20.29 | >20.29–≤25.52 | >25.52–≤32.36 | >32.36 | |||
| Crude | 325/328 | 0.97 (0.62, 1.51) | 1.00 | 1.08 (0.70, 1.67) | 1.24 (0.81, 1.91) | 1.01 (0.65, 1.58) | 0.79 |
| Adjustedd | 323/328 | 1.07 (0.67, 1.73) | 1.00 | 1.08 (0.69, 1.69) | 1.32 (0.85, 2.05) | 1.13 (0.71, 1.79) | 0.43 |
| SHBG | ≤36.75 | >36.75–≤46.35 | >46.35–≤58.20 | >58.20 | |||
| Crude | 328/328 | 1.58 (0.99, 2.52) | 1.00 | 1.96 (1.24, 3.09) | 1.63 (1.03, 2.59) | 1.71 (1.08, 2.71) | 0.09 |
| Adjustede | 323/328 | 1.71 (0.85, 3.44) | 1.00 | 1.94 (1.20, 3.15) | 1.63 (0.96, 2.79) | 1.87 (1.01, 3.44) | 0.12 |
P value for trend from model where quartiles of hormones were entered as ordinal variables.
Model for androgens was adjusted for age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, continuous log-transformed/quartiles of estradiol and SHBG.
Model for estrogens was adjusted for age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, continuous log-transformed/quartiles of testosterone and SHBG.
Model was adjusted for age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, and continuous log-transformed/quartiles of testosterone/estradiol.
Model was adjusted for age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, continuous log-transformed/quartiles of estradiol and testosterone.
Abbreviation: CI, confidence interval; FE2_AE2, free and bioavailable estradiol; FT_AT, free and bioavailable testosterone; OR, odds ratio; SHBG, sex hormone binding globulin.
In subgroup analyses by BMI (Table 3), there were inverse associations of gastric cancer risk with serum FT_AT (OR quartile 4 vs.1=0.37, 95% CI=0.19, 0.72; p-interaction=0.01) and estrone (OR quartile 4 vs.1=0.51, 95% CI=0.27, 0.97; p-interaction=0.22) in lower BMI group. For SHBG, subgroup analysis showed similar association across strata, though there was some evidence for a stronger association in men with BMI>21.2 kg/m2 in lower middle serum concentration (OR quartile 2 vs.1=2.21, 95% CI=1.13, 4.30; p-interaction=0.03). For other sex steroid hormones, subgroup analyses showed comparable and not statistically significantly different results. We also examined the results stratified by age, alcohol drinking, and smoking and did not observe heterogeneity across groups (Supplementary Table 3–5). In general, the Wald tests supported a significant interaction between follow-up time and sex steroid hormones and SHBG (Supplementary Table 6). We found a significant negative association of gastric cancer risk and testosterone in events occurring ≤5 years after baseline. There was effect reversal across three strata of follow-up time for other androgens, estrogens, and SHBG (crossover interactions). When we restricted the subjects to those in the General Population Trial (n=594), the results of sensitivity analysis were similar with the main analysis (Supplementary Table 7).
Table 3.
ORs (95%CIs) for gastric cancer in men associated with quartiles of serum concentrations of androgens, estrogens, and SHBG by BMI subgroup
| BMI (kg/m2) | Case/ controls | Continuous (log10) | Quartile | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N1 | Q1 | N2 | Q2 | N3 | Q3 | N4 | Q4 | p-trenda | p-interaction | |||
| OR (95%CI)b | REF | OR (95%CI)b | OR (95%CI)b | OR (95%CI)b | ||||||||
| Androstenedione | ||||||||||||
| ≤21.2 | 175/150 | 0.82 (0.37, 1.84) | 36/29 | 1.00 | 44/37 | 0.99 (0.51, 1.93) | 45/43 | 0.88 (0.46, 1.72) | 50/41 | 1.07 (0.54, 2.09) | 0.92 | 0.69 |
| >21.2 | 150/177 | 0.97 (0.45, 2.11) | 39/51 | 1.00 | 40/49 | 1.18 (0.64, 2.17) | 39/40 | 1.40 (0.73, 2.67) | 32/37 | 1.23 (0.63, 2.38) | 0.44 | |
| Testosterone | ||||||||||||
| ≤21.2 | 174/151 | 0.50 (0.18, 1.35) | 38/29 | 1.00 | 52/38 | 1.01 (0.52, 1.96) | 46/38 | 0.81 (0.40, 1.66) | 38/46 | 0.50 (0.23, 1.12) | 0.08 | 0.18 |
| >21.2 | 149/177 | 0.93 (0.31, 2.82) | 34/53 | 1.00 | 48/44 | 1.15 (0.59, 2.27) | 37/44 | 0.85 (0.41, 1.73) | 30/36 | 0.84 (0.36, 1.93) | 0.47 | |
| FT_AT | ||||||||||||
| ≤21.2 | 174/150 | 0.42 (0.17, 1.04) | 56/33 | 1.00 | 49/37 | 0.75 (0.40, 1.41) | 38/31 | 0.68 (0.35, 1.30) | 31/49 | 0.37 (0.19, 0.72) | <0.01 | 0.01 |
| >21.2 | 149/177 | 1.22 (0.50, 2.98) | 36/48 | 1.00 | 32/46 | 0.90 (0.47, 1.73) | 44/50 | 1.15 (0.62, 2.12) | 37/33 | 1.40 (0.72, 2.73) | 0.25 | |
| Estradiol | ||||||||||||
| ≤21.2 | 174/151 | 0.87 (0.43, 1.77) | 38/38 | 1.00 | 55/38 | 1.50 (0.80, 2.81) | 46/34 | 1.47 (0.75, 2.87) | 35/41 | 1.00 (0.50, 1.99) | 0.98 | 0.24 |
| >21.2 | 149/177 | 1.92 (0.89, 4.14) | 25/44 | 1.00 | 39/44 | 1.39 (0.70, 2.76) | 42/48 | 1.47 (0.73, 2.93) | 43/41 | 1.77 (0.88, 3.55) | 0.12 | |
| Estrone | ||||||||||||
| ≤21.2 | 173/150 | 0.37 (0.16, 0.85) | 56/34 | 1.00 | 35/34 | 0.59 (0.31, 1.14) | 46/39 | 0.66 (0.35, 1.24) | 36/43 | 0.51 (0.27, 0.97) | 0.06 | 0.22 |
| >21.2 | 149/176 | 1.24 (0.55, 2.79) | 41/47 | 1.00 | 34/48 | 0.78 (0.42, 1.48) | 39/43 | 1.11 (0.59, 2.10) | 35/38 | 1.29 (0.67, 2.50) | 0.32 | |
| FE2_AE2 | ||||||||||||
| ≤21.2 | 174/151 | 0.76 (0.40, 1.45) | 49/41 | 1.00 | 49/38 | 1.06 (0.58, 1.95) | 42/39 | 0.93 (0.50, 1.71) | 34/33 | 0.95 (0.49, 1.83) | 0.77 | 0.28 |
| >21.2 | 149/177 | 1.80 (0.87, 3.72) | 25/41 | 1.00 | 32/44 | 1.08 (0.54, 2.14) | 51/43 | 1.84 (0.95, 3.57) | 41/49 | 1.44 (0.74, 2.80) | 0.14 | |
| SHBG | ||||||||||||
| ≤21.2 | 174/151 | 1.89 (0.70, 5.14) | 25/27 | 1.00 | 44/32 | 1.55 (0.74, 3.22) | 45/45 | 1.18 (0.54, 2.59) | 60/47 | 1.86 (0.78, 4.41) | 0.25 | 0.03 |
| >21.2 | 149/177 | 1.27 (0.46, 3.53) | 27/55 | 1.00 | 57/50 | 2.21 (1.13, 4.30) | 39/37 | 2.03 (0.95, 4.36) | 26/35 | 1.49 (0.60, 3.70) | 0.45 | |
P value for trend from model where quartiles of hormones were entered as ordinal variables.
OR and 95% CI was calculated in adjusted model. Covariates in the model were age (continuous), smoking status, alcohol drinking, BMI (continuous), trial, and other related sex steroid hormones or SHBG.
Abbreviation: BMI, body mass index; CI, confidence interval; FE2_AE2, free and bioavailable estradiol; FT_AT, free and bioavailable testosterone; OR, odds ratio; SHBG, sex hormone binding globulin.
Discussion
This is the first study to prospectively examine the association between prediagnostic serum sex steroid hormones concentrations and SHBG and the risk of non-cardia gastric cancer in a population-based setting among Chinese men. There were no overall associations between sex steroid hormone concentrations and risk of developing gastric cancer, but we observed some evidence for novel association for higher serum SHBG concentrations. Additionally, higher baseline serum estrone and FT_AT concentrations was inversely associated with risk of gastric cancer among subjects with BMI≤21.2 kg/m2 and evidence for a quantitative interaction such that the direction of the association was the opposite among heavier men. Given that this interaction was not predicted a priori and the result may be provisional and we need further studies to evaluate whether these associations reflect a real pattern or are spurious. Of note, our population has relatively low distribution of BMIs even for a population within China. A large fraction of men were underweight at the time of blood sample collection, which may directly alter typical levels of both sex steroid hormones and SHBG.
To our knowledge, few previous studies have explored the association between serum SHBG concentrations and the risk of gastric cancer, and none of the previous data have suggested a positive association prospectively. An Indian study of 50 subjects found a 2.3-fold increased expression in serum SHBG of gastric cancer patients across 643 proteins (31). Another case-control study of 86 healthy subjects and 98 gastric cancer patients conducted in Taiwan, China found a consistently higher serum levels of SHBG among gastric cancer patient groups compared with that of the controls (32). Nevertheless, the two studies collected blood samples at diagnosis and thus could reflect reverse causation, whereby the tumor or other disease processes, such as cachexia, could affect sex steroid hormones concentrations (31,32). Petrick et al. examined the association between prediagnostic concentrations of circulating sex steroid hormones and esophageal/gastric cardia adenocarcinoma risk among men from three western cohorts, which have significantly different etiology from non-cardia gastric cancer studied here and did not observe an association (8).
SHBG is a plasma glycoprotein that transports androgens and estrogens while in circulation and regulates the bioavailability of free estrogens and androgens (33). Bioavailable estradiol has the potential ability to attenuate tumor malignancy by inducing apoptosis and reducing cell viability in gastric cancer cells (34), providing indirect evidence in accordance with our findings for SHBG and gastric cancer. Research in the past decade suggest that cell membranes of many tissues could express a receptor for SHBG (35). Binding of SHBG to its receptor has been shown to activate cyclic adenosine monophosphate (36), an intracellular signal transduction pathway important for many biological processes including cancer growth, which may independent from its role in hormone transport (37).
Many studies report that SHBG concentrations are negatively associated with BMI (38,39). This inverse correlation is also observed at in the current study (Pearson’s R=−0.2064, P<0.01). This is thought to occur because adipose cells increase the circulating levels of insulin and increase insulin-like growth factor 1 (IGF1) bioactivity (40) and finally result in reduced hepatic synthesis and blood concentrations of SHBG (41), which suggests that the effect measures of SHBG may be more substantial among slim men. Studies of BMI related androgens and estrogens concentrations change among men are inconclusive (42–45). Further work including men with a wider range of BMI is needed to replicate these associations and infer a possible mechanism underlying our observations.
This study has several strengths in design and analysis. It was the first to investigate the association of gastric cancer with prediagnostic sex steroid hormones and SHBG in an Asian population. The study population was highly homogeneous regarding to occupation and socioeconomic status. With the 15 years of post-trial follow-up between baseline blood draw and cancer diagnosis, minimal loss to follow-up rate (1%), and extensive information on potential confounders, we were able to evaluate the associations prospectively and conduct analyses adjusted for and stratified by major risk factors. However, we should also note the limitations of this study, which include a modest sample size. In addition, we do not have complete data on Helicobacter pylori seropositivity, pepsinogen I/II ratio (27,46) and lack data on other serologic factors (47–48) (e.g. fasting insulin, insulin-like growth factor 1 and inflammatory biomarkers), which may confound the associations between sex hormones and risk of gastric cancer. Our previous study found that individuals with low pepsinogen I/II ratios had higher risk of non-cardia gastric cancer (27) and another study found that estradiol and androstenedione have the potential to inhibit the growth of Helicobacter pylori (46). A further limitation is that we only had a single blood draw, and misclassification of sex steroid hormones and SHBG could not be excluded.
In conclusion, there were no overall associations between androgens and estrogens and risk of non-cardia gastric cancer in men. Higher concentration of SHBG was associated with increased risk of gastric cancer. We found some evidence for associations of sex steroid hormones in men with lower BMIs. Studies of sex steroid hormones and gastric cancer in women are needed to fully explore this hypothesis and further explore whether BMI will modify the association.
Supplementary Material
Prevention Relevance Statement:
It was the first study to investigate the association of gastric cancer with prediagnostic sex steroid hormones and SHBG in an Asian male population. Although there were no overall associations for sex steroid hormone concentrations, higher concentrations of SHBG was associated with increased risk of non-cardia gastric cancer.
Acknowledgments
Funding source:
This work was supported in part by National Cancer Institute contracts (N01-SC-91030, N01-RC-47701 and N02CP-2017-00047 to YL. Qiao) to the National cancer center, Chinese Academy of Medical Sciences, in part by the National Cancer Center, Chinese Academy of Medical Sciences, and in part by the Intramural Research Program of the National Cancer Institute, NIH.
Abbreviation list:
- CI
confidence interval
- FE2_AE2
free and bioavailable estradiol
- FT_AT
free and bioavailable testosterone
- NIT
Nutrition Intervention Trial
- SHBG
sex hormone binding globulin
Footnotes
Conflict of interest: The authors declare no conflict of interest
Ethics approval: This study was conducted with the approval of the US National Institutes of Health and the Chinese Academy of Medical Sciences.
The study was conducted in accordance with the Declaration of Helsinki.
References
- 1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424 doi 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
- 2.Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett 2017;401:63–71 doi 10.1016/j.canlet.2017.04.024. [DOI] [PubMed] [Google Scholar]
- 3.Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66(2):115–32 doi 10.3322/caac.21338. [DOI] [PubMed] [Google Scholar]
- 4.Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, Fan JH, et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 2007;96(1):172–6 doi 10.1038/sj.bjc.6603517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008;44(16):2397–403 doi 10.1016/j.ejca.2008.07.031. [DOI] [PubMed] [Google Scholar]
- 6.Freedman ND, Derakhshan MH, Abnet CC, Schatzkin A, Hollenbeck AR, McColl KEL. Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. Eur J Cancer 2010;46(13):2473–8 doi 10.1016/j.ejca.2010.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ibrahim A, Morais S, Ferro A, Lunet N, Peleteiro B. Sex-differences in the prevalence of Helicobacter pylori infection in pediatric and adult populations: Systematic review and meta-analysis of 244 studies. Dig Liver Dis 2017;49(7):742–9 doi 10.1016/j.dld.2017.03.019. [DOI] [PubMed] [Google Scholar]
- 8.Petrick JL, Hyland PL, Caron P, Falk RT, Pfeiffer RM, Dawsey SM, et al. Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. J Natl Cancer Inst 2019;111(1):34–41 doi 10.1093/jnci/djy082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21(1):20–38 doi 10.1158/1055-9965.EPI-11-0834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer 2014;120(17):2735–41 doi 10.1002/cncr.28769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Liao C-H, Li H-Y, Yu H-J, Chiang H-S, Lin M-S, Hua C-H, et al. Low serum sex hormone-binding globulin: marker of inflammation? Clin Chim Acta 2012;413(7–8):803–7 doi 10.1016/j.cca.2012.01.021. [DOI] [PubMed] [Google Scholar]
- 12.Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, McKinlay JB. Association of sex hormones and C-reactive protein levels in men. Clin Endocrinol (Oxf) 2010;72(4):527–33 doi 10.1111/j.1365-2265.2009.03713.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Maggio M, Basaria S, Ceda GP, Ble A, Ling SM, Bandinelli S, et al. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 2005;28(11 Suppl Proceedings):116–9. [PubMed] [Google Scholar]
- 14.Kang M-H, Choi H, Oshima M, Cheong J-H, Kim S, Lee JH, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nat Commun 2018;9(1):1920 doi 10.1038/s41467-018-04244-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002;128(6):319–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ryu W-S, Kim J-H, Jang Y-J, Park S-S, Um J-W, Park S-H, et al. Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol 2012;106(4):456–61 doi 10.1002/jso.23097. [DOI] [PubMed] [Google Scholar]
- 17.Freedman ND, Chow W-H, Gao Y-T, Shu X-O, Ji B-T, Yang G, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 2007;56(12):1671–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Moore SC, Matthews CE, Ou Shu X, Yu K, Gail MH, Xu X, et al. Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women. J Natl Cancer Inst 2016;108(10) doi 10.1093/jnci/djw103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993;85(18):1492–8. [DOI] [PubMed] [Google Scholar]
- 20.Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85(18):1483–92. [DOI] [PubMed] [Google Scholar]
- 21.Wang S-M, Taylor PR, Fan J-H, Pfeiffer RM, Gail MH, Liang H, et al. Effects of Nutrition Intervention on Total and Cancer Mortality: 25-Year Post-trial Follow-up of the 5.25-Year Linxian Nutrition Intervention Trial. J Natl Cancer Inst 2018;110(11):1229–38 doi 10.1093/jnci/djy043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007;16(9):1713–9 doi 10.1158/1055-9965.Epi-06-0765. [DOI] [PubMed] [Google Scholar]
- 23.Ranadive GN, Mistry JS, Damodaran K, Khosravi MJ, Diamandi A, Gimpel T, et al. Rapid, convenient radioimmunoassay of estrone sulfate. Clin Chem 1998;44(2):244–9. [PubMed] [Google Scholar]
- 24.Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16(6):801–10 doi 10.1016/0022-4731(82)90038-3. [DOI] [PubMed] [Google Scholar]
- 25.Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 2000;9(4):403–12. [PubMed] [Google Scholar]
- 26.Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci 2004;17 Suppl. [PubMed] [Google Scholar]
- 27.Wang S-M, Roth MJ, Murphy GA, Dawsey SM, Fan J-H, Taylor PR, et al. Serologic Profile of Antiparietal Cell Antibodies, Pepsinogens, and and Risk of Upper Gastrointestinal Cancer: A Nested Case-Control Study in China. Cancer Epidemiol Biomarkers Prev 2019;28(12):2022–9 doi 10.1158/1055-9965.EPI-19-0512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yu S, Qiu L, Liu M, Li S, Tao Z, Zhang Q, et al. Establishing reference intervals for sex hormones and SHBG in apparently healthy Chinese adult men based on a multicenter study. Clin Chem Lab Med 2018;56(7):1152–60 doi 10.1515/cclm-2017-0749. [DOI] [PubMed] [Google Scholar]
- 29.Calderón B, Gómez-Martín JM, Vega-Piñero B, Martín-Hidalgo A, Galindo J, Luque-Ramírez M, et al. Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. Andrology 2016;4(1):62–7 doi 10.1111/andr.12135. [DOI] [PubMed] [Google Scholar]
- 30.Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev 2013;22(8):1395–408 doi 10.1158/1055-9965.EPI-13-0042. [DOI] [PubMed] [Google Scholar]
- 31.Subbannayya Y, Mir SA, Renuse S, Manda SS, Pinto SM, Puttamallesh VN, et al. Identification of differentially expressed serum proteins in gastric adenocarcinoma. J Proteomics 2015;127(Pt A):80–8 doi 10.1016/j.jprot.2015.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Cheng C-W, Chang C-C, Patria YN, Chang R-T, Liu Y-R, Li F-A, et al. Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer. Cancer Med 2018;7(1):64–74 doi 10.1002/cam4.1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hammond GL. Potential functions of plasma steroid-binding proteins. Trends Endocrinol Metab 1995;6(9–10):298–304. [DOI] [PubMed] [Google Scholar]
- 34.Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X, et al. The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells. Mol Cell Biochem 2014;395(1–2) doi 10.1007/s11010-014-2115-2. [DOI] [PubMed] [Google Scholar]
- 35.Avvakumov GV, Cherkasov A, Muller YA, Hammond GL. Structural analyses of sex hormone-binding globulin reveal novel ligands and function. Mol Cell Endocrinol 2010;316(1):13–23 doi 10.1016/j.mce.2009.09.005. [DOI] [PubMed] [Google Scholar]
- 36.Rosner W, Hryb DJ, Kahn SM, Nakhla AM, Romas NA. Interactions of sex hormone-binding globulin with target cells. Mol Cell Endocrinol 2010;316(1):79–85 doi 10.1016/j.mce.2009.08.009. [DOI] [PubMed] [Google Scholar]
- 37.Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res 2004;64(4):1338–46. [DOI] [PubMed] [Google Scholar]
- 38.Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45(6):1211–9. [DOI] [PubMed] [Google Scholar]
- 39.Jensen TK, Andersson A-M, Jørgensen N, Andersen A-G, Carlsen E, Petersen JH, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 2004;82(4):863–70. [DOI] [PubMed] [Google Scholar]
- 40.Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3(3):157–72. [DOI] [PubMed] [Google Scholar]
- 41.Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579–91. [DOI] [PubMed] [Google Scholar]
- 42.Grasa MDM, Gulfo J, Camps N, Alcalá R, Monserrat L, Moreno-Navarrete JM, et al. Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. Eur J Endocrinol 2017;176(4):393–404 doi 10.1530/EJE-16-0834. [DOI] [PubMed] [Google Scholar]
- 43.Tchernof A, Després JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000;32(11–12):526–36. [DOI] [PubMed] [Google Scholar]
- 44.Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009;11(5):212 doi 10.1186/bcr2413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Frycz BA, Murawa D, Wysocki-Borejsza M, Marciniak R, Murawa P, Drews M, et al. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer. Biomed Pharmacother 2013;67(7):651–7 doi 10.1016/j.biopha.2013.06.012. [DOI] [PubMed] [Google Scholar]
- 46.Hosoda K, Shimomura H, Hayashi S, Yokota K, Hirai Y. Steroid hormones as bactericidal agents to Helicobacter pylori. FEMS Microbiol Lett. 2011. May;318(1):68–75. [DOI] [PubMed] [Google Scholar]
- 47.Kwon HJ, Park MI, Park SJ, Moon W, Kim SE, Kim JH, Choi YJ, Lee SK. Insulin Resistance Is Associated with Early Gastric Cancer: A Prospective Multicenter Case Control Study. Gut Liver. 2019. Mar 15;13(2):154–160. doi: 10.5009/gnl17556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Ennishi D, Shitara K, Ito H, Hosono S, Watanabe M, Ito S, et al. Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population. Cancer Sci. 2011. December;102(12):2231–5. doi: 10.1111/j.1349-7006.2011.02062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.